Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)

被引：0
作者：
Teran Brage, E. [1 ]
Reguera Puertas, P. [1 ]
Campana-Diaz, E. [2 ]
Navarro Martin, M. [1 ]
Garcia Talavera, P. [2 ]
Rama Alonso, S. [2 ]
Lopez Gutierrez, A. [1 ]
Roldan Ruiz, J. [1 ]
Garijo Martinez, M. D. C. [1 ]
Morchon Araujo, D. [1 ]
Posado-Dominguez, L. [1 ]
Redondo Gonzalez, J. C. [1 ]
Diaz Sanchez, P. [1 ]
Pablo Martin, E. [1 ]
Felix, L. C. [1 ]
Lozano Mejorada, R. [1 ]
Fonseca Sanchez, E. [1 ]
机构：
[1] Univ Hosp Salamanca, Med Oncol Dept, Salamanca, Spain
[2] Univ Hosp Salamanca, Nucl Med Dept, Salamanca, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1163P
引用
收藏
页码：S758 / S759
页数：2
相关论文
共 50 条
  • [41] Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT)
    Chauhan, A.
    Binder, P.
    Tesfaye, E.
    Seth, K.
    Lapuerta, P.
    PANCREAS, 2021, 50 (03) : 447 - 448
  • [42] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
    Alayli, Adam
    Ngo, Hoang
    Sikaria, Dhiraj
    Ahmed, Altan
    Salloum, Elias
    Strosberg, Jonathan R.
    Al-Toubah, Taymeyah E.
    Kis, Bela
    Haider, Mintallah
    El-Haddad, Ghassan
    CANCERS, 2024, 16 (15)
  • [43] Quality Of Life in Patients with Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy
    Wang, Q.
    Librizzi, D.
    Bagheri, S.
    Ebrahimifard, A.
    Luster, M.
    Yousefi, B. H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S246 - S247
  • [44] Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)
    Schiavo Lena, Marco
    Partelli, Stefano
    Castelli, Paola
    Andreasi, Valentina
    Smart, Chanel Elisha
    Pisa, Eleonora
    Bartolomei, Mirco
    Bertani, Emilio
    Zamboni, Giuseppe
    Falconi, Massimo
    Doglioni, Claudio
    ENDOCRINE PATHOLOGY, 2020, 31 (02) : 119 - 131
  • [45] The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs).
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Peptide receptor radiotherapy (PRRT) as a potential tool of neoadjuvant therapy in patients with inoperable neuroendocrine tumors (NETs)
    Sowa-Staszczak, Anna
    Pach, Dorota
    Stefanska, Agnieszka
    Tomaszuk, Monika
    Mikolajczak, Renata
    Pawlak, Dariusz
    Trofimiuk, Malgorzata
    Chrzan, Robert
    Hubalewska-Dydejczyk, Alicja
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [47] Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?
    Mileva, M.
    Marin, G.
    Levillain, H.
    van Bogaert, C.
    Critchi, G.
    Marin, C.
    Flamen, P.
    Karfis, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 153 - 153
  • [48] Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
    Kwekkeboom, Dik J.
    Krenning, Eric P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (01) : 179 - +
  • [49] Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
    Bodei, Lisa
    Cremonesi, Marta
    Kidd, Mark
    Grana, Chiara M.
    Severi, Stefano
    Modlin, Irvin M.
    Paganelli, Giovanni
    THORACIC SURGERY CLINICS, 2014, 24 (03) : 333 - +
  • [50] Peptide receptor radionuclide therapy (PRRNT) in metastatic neuroendocrine tumors (NETs) arising from the kidney
    Prasad, Vikas
    Kulkarni, Harshad
    Zachert, Carolin
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
12345